Results 191 to 200 of about 73,182 (252)

Regulatory T Cells in Health and Disease

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Regulatory T cells (Tregs) arise through distinct developmental pathways and adapt to specialized tissue niches to maintain immune tolerance, barrier integrity, and metabolic homeostasis. In disease, Tregs undergo context‐dependent changes, ranging from functional insufficiency and lineage instability in autoimmune, inflammatory, cardiovascular, and ...
Mingyi Li   +4 more
wiley   +1 more source

OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

open access: yesMedComm, Volume 7, Issue 11, November 2026.
OTUD1 interacts with AKT and decreases AKT‐mTOR pathway activity, facilitating the translocation of TFEB to the nucleus, thereby triggering autophagy‐dependent degradation of PD‐L1 in lysosomes. . ABSTRACT Upregulation of PD‐L1 on tumor cells is a pivotal aspect of immune evasion, leading to treatment resistance, tumor recurrence, and metastasis ...
Yang Hao   +10 more
wiley   +1 more source

A Pan‐Hepatic T‐Cell Atlas Identifies Disease‐Specific Immune Dysfunction and Therapeutic Targets for Immunotherapy

open access: yesMedComm, Volume 7, Issue 11, November 2026.
A Pan‐HEpatic single‐cell Atlas of T cells (Pheat) was constructed covering chronic hepatitis, cirrhosis, hepatocellular carcinoma (HCC), and healthy controls. CD8+ exhausted T cells (Tex) and CD4+ regulatory T cells (Treg) were delineated profound through decoding molecular and cellular variance, immune checkpoint networks, pathway analysis, and drug ...
Si‐Yuan Chen   +18 more
wiley   +1 more source

Antibody–Drug Conjugates and Radionuclide‐Conjugated Drugs in Cancer Therapy: Mechanisms, Clinical Advances, and Future Directions

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Radionuclide‐conjugated drugs (RDCs) integrate molecular targeting, quantitative imaging, and dosimetry to enable image‐guided precision cancer theranostics. Through coordinated ligand–chelator–radionuclide design, RDCs support patient selection, targeted radiation delivery, response monitoring, and adaptive treatment optimization, providing a ...
Chen Fu   +7 more
wiley   +1 more source

Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer. [PDF]

open access: yesFront Cell Dev Biol
Bautista J   +5 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy